June 12, 2014 Below is a pdf for MTSL Issue #781 of the Medical Technology Stock Letter.
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.
Tag: INCY
MTSL Issue #779 – Not Your Father’s Platforms
May 15, 2014 Below is a pdf for Issue 779 of the Medical Technology Stock Letter.
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.
INCY’s IDO and A Visit to Novavax
INCY’s IDO & Cancer Immunotherapy – Treating cancer with immunotherapy has become one of the major “Hot New Classes†over the last year as the science, compounds and subsequent studies have demonstrated the ability to significantly extend the lives of cancer patients.
THE NEW CLASSES ARE IN SESSION
The pharmaceutical and biotechnology industries have gone through periods of blockbuster drug classes, which has often resulted in one or more leading drugs catapulting the respective company’s growth rates and, in many cases, market capital, to the very top of the industry.
MTSL Issue #780 – The FDA Clinical Trials Process – A Primer
May 29, 2014 Below is a pdf for Issue 780 of the Medical Technology Stock Letter.
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.
MTSL Issue #772 – First Half 2014 Event Calendar
February 6, 2014 Below is a pdf for MTSL Issue #772 of the Medical Technology Stock Letter.
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.
MTSL Issue #768 – INCY’s IDO & A Visit to NVAX
December 5, 2013 Below is a pdf for MTSL Issue #768 of the Medical Technology Stock Letter.
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.
INCY KNOWS JAKS
INCY – KNOWS JAKS– RAISING BUY LIMIT & TARGET – INCB039110 Shows Promise with Proof-of-Concept Data in Both Psoriasis & RA, MF Next Up at ASH
NOT YOUR FATHER’S PLATFORMS
MTSL published Issue #753 “Plentiful Platforms†on April 25, 2012. Most of our platform recommendations have made significant progress since then, and our subscriber base has grown substantially as well.
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.
INCY & ISIS – THE NEXT PHASE
CHASING INCY – INCY Poised to Emerge as Oncology Powerhouse, Raising BUY LIMIT – The biggest driver of INCY’s value over the last year, and in our view, going forward has been the emergence of their oncology pipeline.
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.
ORAL ARGUMENTS
Historically, classic biotech companies developed monoclonal antibodies and proteins as new therapies for hard-to-treat conditions. There have been multiple examples of blockbuster successes (e.g., EPO, anti-TNF antibodies, HGH, human insulin, etc.) leading the past 30+ years to create the Biotechnology sector.
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.
Incyte Update (8-21-13)
Incyteâs Jakafi Delivers Great Phase II Pancreatic Data:Â Incyte (INCY) has reported great top-line results from their Phase II, randomized, double-blind, placebo-controlled RECAP trial of Jakafi in combination with capecitabine in patients with recurrent or treatment refractory metastatic pancreatic cancer. The hazard ratio (HR) for overall survival (OS) in the intent to treat population was[…]
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.